Novo Nordisk

News

Novo Nordisk joins molecular glue club with Neomorph deal

Big pharma’s interest in using protein degradation as a therapeutic strategy shows no sign of abating, as Novo Nordisk signs a wide-ranging deal with US biotech Neomorph t

News

Could Novo-Catalent deal face antitrust hurdles?

Eli Lilly has called on financial regulators to look into the antitrust implications of Novo Holdings' purchase of Catalent and the sale of three manufacturing facilities

News

Novo Nordisk tackles supply issues with $11bn Catalent deal

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging

News

Novo Nordisk sales surge drives value towards $500bn

Fuelled by its diabetes and obesity drugs, Novo Nordisk has reported revenues up a third in 2023, sparking a rise in an already inflated share price that briefly pushed th

News

Britain will be first to get new Mounjaro device, says Lilly

Eli Lilly is just weeks away from launching Mounjaro in the UK, after getting approval from medicines regulator, the MHRA, for a new formulation of the drug as a treatment

News

FDA finds no link between GLP-1 drugs and suicide

The FDA has given an update on its ongoing review of a possible link between GLP-1 agonist drugs used to treat diabetes and obesity and suicide, saying it can find no evid

Novo Nordisk joins molecular glue club with Neomorph deal

Could Novo-Catalent deal face antitrust hurdles?

Novo Nordisk tackles supply issues with $11bn Catalent deal

Novo Nordisk sales surge drives value towards $500bn

Britain will be first to get new Mounjaro device, says Lilly

FDA finds no link between GLP-1 drugs and suicide

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Novo Nordisk

Editor's Picks